Skip to content

The effectiveness of a personalized executive functioning training program for pre-schoolers with a severe congenital heart disease.

The effectiveness of a personalized executive functioning training program for pre-schoolers with a severe congenital heart disease. - Learning by Heart

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56699
Enrollment
108
Registered
2023-10-30
Start date
2024-05-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease

Interventions

The investigated intervention is the personalised training program *KleuterExtra*, developed by dr. Lex Wijnroks from Utrecht University. *KleuterExtra* consists of an EF test battery and an EF-trai

Sponsors

Stichting Hartekind
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a child must meet all of the following criteria:Aged 4.0 - 6.0 years upon inclusion OR aged 6.0-7.0 years who are still in kindergarten (group 1 & 2 of the Dutch school system)Required CHD surgery in the first six months of life (with or without ECMO) or a cyanotic CHD that required surgery in the first 12 months of lifeIQ estimated > 55 (no moderate to severe intellectual disability)Diminished EF based on a below average score on any of the subtests of the ‘KleuterExtra’ test battery (= 21 percentile) at t = 0 Sufficient comprehension of the Dutch language by the child to be able to participate in the EF test battery and the EF training program. In order to be eligible to participate in this study, the parent(s) must meet the following criteria:Sufficient comprehension of the Dutch language to understand the study information and to be able to fill out the Dutch questionnaires.

Exclusion criteria

Exclusion criteria: - Children receiving targeted EF support at school upon inclusion. - Children with severe brain damage (estimated IQ < 55) - Genetic syndromes known to directly affect cognitive performance (e.g. Down  syndrome) - Children with severe psychiatric disorders upon inclusion that require treatment first, such as a posttraumatic stress disorder, separation anxiety disorder, or reactive attachment disorder.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is a single composite score on the *Kleuter Extra* EF test battery, at 9 weeks after baseline.

Secondary

MeasureTime frame
Tests (child): - EF functioning: single test scores from the **Kleuter Extra** EF test battery - Information processing: Cognitive Proficiency Index of the WPPSI-IV-NL Questionnaires (both parents): - Executive functioning of the child in daily life: BRIEF-P - Behavioral and emotional difficulties of the child: CBCL (1.5- 5 years old) - Quality of the child*s life: TAPQL - Emotional distress of the parent: DASS-21 - Parental trauma: PCL-5 - Parenting behavior and quality parent-child relationship: PABI - Subjective evaluation questionnaires regarding the book *Speels Brein* (*Playful brain*) and if applicable, the training program. Questionnaires (teacher): - Child demographics: additional support in school, type, being held back a year - Behavioral and emotional difficulties of the child: TRF - Executive functioning of the child in daily life: BRIEF-teacher All primary and secondary parameters, except the subjective evaluation questionnaires, will be assessed at baseline, 9 weeks, and 6 and 12-months follow-up measures. The subjective evaluation questionnaire regarding the book *Speels Brein* (*Playful Brain*) will be administered at the three follow-up measures. The subjective evaluation questionnaire regarding the training program will be administered once, at the 9 weeks follow-up measure. Please refer to 8.3.2. *Study assessments* in the study protocol for a more detailed description.

Countries

Netherlands

Contacts

Public ContactR. Schappin

Erasmus MC, Universitair Medisch Centrum Rotterdam

r.schappin@erasmusmc.nl06-46404707

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)